Elizabeth Abosede Ogunrinde, MD, PHD
Psychiatry · Palo Alto
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ogunrinde’s office at (650) 723-5511 to ask if they take your plan before you enroll.
Drugs they prescribed that Part D paid
$35,664
Pharmacies billed $35,664 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 179) in 2024. At or below the middle of the specialty; the typical psychiatry & neurology clinician is at 0%.
164 generic and 15 brand-name prescriptions · $35,664 in drug cost · 19 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Quetiapine | 26 | $391 | $15 |
| Fluoxetine | 13 | $155 | $12 |
| Hydroxyzine Pamoate | 11 | $127 | $12 |
| Trazodone | 22 | $115 | $5 |
Year by year
| 2024 | 179 | 40 | 0% (0) | 8% | $35,664 |
| 2022 | 14 | None | 0% (0) | None | $626 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$122 in 2025
| 2025 | 2 | 2 | None | $122 |
| 2024 | 7 | 10 | None | $771 |
| 2023 | 1 | 1 | None | $38 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Tris Pharma | Onyda Xr | $104 | 1 payment
|
| Otsuka America Pharmaceutical | Abilify Asimtufii | $17 | 1 payment
|
See all 2 published payments
| Tris Pharma | Meals · 2025-05-14 | Onyda Xr | $104 |
| Otsuka America Pharmaceutical | Meals · 2025-02-12 | Abilify Asimtufii | $17 |
See earlier years (2024, 2023)
2024: $771
| Otsuka America Pharmaceutical | Rexulti | $256 | 3 payments
|
| Janssen Pharmaceuticals | Spravato | $128 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $122 | 1 payment
|
| Alkermes | Lybalvi | $116 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $98 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $26 | 1 payment
|
| Abbvie | Vraylar | $25 | 1 payment
|
2023: $38
| Merz Pharmaceuticals | Xeomin | $38 | 1 payment
|
Professional record
- NPI
- 1699354803
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X); Student in a training program (390200000X)
- Mailing address
- 401 Quarry Rd Rm 2206, Palo Alto, CA, 94304
- NPI first listed
- 2021-04-05
- NPI last updated
- 2026-08-06
- NPI record certified
- 2026-08-06
This is when the NPI record was last certified, not a medical board exam.